GS-012 Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: week 96 endpoint results from the phase 2 SOLSTICE trial

Journal of Hepatology 2026

View at publisher
Authors: Tarik Asselah, Anca Streinu-Cercel, Alina Jucov, Edward J. Gane, Heiner Wedemeyer, Pietro Lampertico, Patrick Kennedy, Michael A. Chattergoon, Bria Bullard, Cheng Huang, Rima Acosta, Cara Pilowa
+2 more Todd Correll, Kosh Agarwal
DOI: 10.1016/s0168-8278(26)00304-1
Cited by: 2

Fields of Study & Subjects

Hepatitis B Virus Studies Hepatitis C virus research HIV/AIDS drug development and treatment

Publication details

Journal / source
Journal of Hepatology
Publisher
Elsevier BV
Volume
84
Pages
S7–S7
Publication date
1 May 2026
Language
EN